Form 10-K SKINVISIBLE, INC. For: Dec 31

TABLE
OF CONTENTS

PART I

Recent Developments

On October 17, 2019, we entered an Exclusive License Agreement with
Quoin Pharmaceuticals, Inc., a Delaware corporation (“Quoin”)pursuant to which we granted to Quoin a license to certain
patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to pay to us a license fee
of $1,000,000 (the “License Fee”) and a single digit royalty interest of all net sales on the licensed products subject
to adjustment in certain situations. The agreement also requires that Quoin make certain milestone payments to us upon achieving
regulatory approval milestones for certain drug products.

The
agreement is subject to termination, if among other things, 50{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of the license fee is not paid by December 31, 2019 and if the
full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated. Both Parties subsequently
determined that they continue to see the value in a partnership and therefore on May 8, 2020 and again on July 31, 2020 the companies
agreed to extend the Exclusive License Agreement under the same terms to expire on September 30, 2020  ,
and on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement
indefinitely. As of December 31, 2020, we have received $125,000 in licensing fee income per this agreement.

On February 3, 2020, we entered into a License Agreement with Ovation
Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture and distribution rights
to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to Skinvisible a royalty
percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee payable in
year 3 of the agreement if it chooses to continue the license. On June 10, 2020, the agreement was further amended to provide additional
assignment rights for its hand sanitizer products in exchange for $100,000 which was recognized as revenue during the year ended
December 31, 2020.

Company Overview

We, through our wholly owned subsidiary Skinvisible
Pharmaceuticals Inc., are a pharmaceutical research and development (“R&D”) company that has developed and patented
an innovative polymer delivery system, Invisicare® and formulated over forty topical skin products, which we out-license globally.
We were incorporated in 1998, and target an estimated $80 billion global skincare and dermatology market and a $30 billion global
over-the-counter market as well as other healthcare / medical and consumer goods markets.

With the research and development complete on forty products
and numerous patents issued (technology and product patents), we are ready to monetize our investment. Our business model will
continue to be to out-license our patented prescription and over-the-counter (“OTC”) products featuring Invisicare
to established manufacturers and marketers of brands internationally and to maximize profits from the products we have already
out-licensed.

The opportunity for us to license our products continues to be a
viable model as the need for pharmaceutical companies to access external R&D companies for new products due to their own down-sizing
or elimination of internal R&D departments. The demand for our products is enhanced due to the granting of key US and international
patents and the completed development of a number of unique products.

Our Flagship Product

Pivotal to our success is our patented polymer delivery system technology
Invisicare. Invisicare is a patented polymer delivery system that enhances the delivery of active ingredients for topically applied
skin care products. Its patented technology has a unique formula and process for combining active ingredients with a delivery system
that extends the duration of time the product remains on the skin and active.

Invisicare is specifically formulated to carry water insoluble
active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic
solvents. Products utilizing Invisicare have the proven ability to bond active ingredients to the skin for up to four hours and
longer. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure
from a wide variety of environmental irritants.

When topically applied, these formulated products adhere to the
skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare
agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer
duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions
wear off as part of the natural exfoliation process of the skin’s outer layer cells.

The advantage of products formulated with Invisicare is (1) Invisicare’s
ability to bind active ingredients (the drug) to the skin, forming a protective bond on the skin, for extended periods of time;
(2) Invisicare can deliver targeted levels (high or low) of therapeutic or cosmetic ingredients to the skin in a controlled release;
(3) Invisicare can help to reduce the irritation of some active ingredients due to how it controls the slower release of that active
ingredient; and (4) Invisicare science proves that it provides a protective skin barrier which helps retain the natural moisture
content of the skin, while still allowing it to breathe. These benefits present an excellent opportunity for clear scientific advantages
and marketing messages which resonate with physicians and consumers.

The Market

The dermatology market is large, with over 80{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of Americans affected
by some kind of skin condition in their lifetime. The worldwide market for dermatology products including prescription, OTC and
cosmeceuticals is estimated at $80 billion.

Company
History

We formed Skinvisible Pharmaceuticals, Inc. (“Skinvisible”),
in March 1998 and purchased the exclusive worldwide manufacturing and marketing rights for a polymer delivery system invention
now called Invisicare® from the inventor for $2 million. We have continued to develop the Invisicare technology and subsequent
product development resulting in over seven series of Invisicare and over forty unique, patented formulations offering distinctive
benefits that differentiate them significantly from other leading products in the marketplace.

What We Do

We have positioned ourselves in the $80 billion worldwide prescription
and over-the-counter dermatology and skincare market. We generate revenue by:

• LICENSING: We develop topical prescription and over-the-counter
  products enhanced with Invisicare to license to pharmaceutical and consumer goods companies around the world for an upfront fee
  and ongoing royalties;
• CO-DEVELOPMENT: We assist pharmaceutical clients in the
  early development of the most optimal formulation, which they then take forward into clinical testing;
• LIFE CYCLE MANAGEMENT: We provide cost-effective solutions
  to global pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent and new product
  benefits and line extensions. Pharmaceutical companies are under a lot of pressure to develop innovative strategies to counteract
  the revenue loss from their drugs coming off patent.

Corporate Ownership

We are a publicly traded company under the symbol SKVI, quoted on
the OTC markets since February 1999 and currently trading on the OTCQB in the United States.

We carry on business primarily through our wholly owned subsidiaries:
Skinvisible Pharmaceuticals, Inc. a Nevada corporation.

Patents

We have patents granted in 11 countries, including comprehensive
patents on Invisicare, the foundation of all of our products; the United States, and internationally in Canada, Europe (4), China,
India, Australia, Hong Kong, and Korea. The Invisicare patents cover manufacturing, composition and use. Additionally, we have
been granted product specific patents in the United States for dermal barrier products, sunscreens (photostability of avobenzone),
retinoids (stabilization), cationic products and acne products.

Our value lies in our ability to continually generate new IP on
dermatology and medical products formulated with Invisicare. Patent approvals are sought (initially in the United States. and later
internationally) for all products developed. All patents with Invisicare are owned by us.

Trademarks

When developing new products using Invisicare, we file for both
patent and trademark protection. We have been granted trademarks in the U.S. and Canada for the following names:

– Skinvisible® w Invisicare® w JUSTCARE® w Kintari®
w Skinbrella®

Revenue generation: We plan to achieve revenues from a combination
of four revenue streams including:

Strategic Growth Opportunities

Our growth strategy is to:

Private Label Products

Our sunscreen is a broad spectrum SPF 30 known as Skinbrella®.
We completed independent testing to validate our broad spectrum sunscreen claims according to the labeling guidelines of the FDA,
which are designed to help reduce the incidents of skin cancer in the U.S. Our claims are as follows:

• Claim # 1 – Broad-Spectrum: According to the FDA, in order
  for a sunscreen to be labeled “broad spectrum” it must prove it protects against both UVA and UVB rays by having an
  SPF (Sun Protection Factor) of at least 15 and a critical wave length of at least 370 nm. Our sunscreen has surpassed both of these
  criteria, allowing our broad spectrum sunscreen label to also state “prevents sunburn, skin cancer and aging due to the sun.”

• Claim # 2 – Water-Resistant 80 Minutes: The FDA sunscreen
  water resistant claim requires that a sunscreen must have the same SPF after being in water or sweating for 40 or 80 minutes. Our
  testing was conducted at an independent laboratory specializing in sunscreen testing. The test involved human subjects that applied
  sunscreen to their arm, followed by the immersion of the arm into a Jacuzzi for 80 minutes (10 minutes in / 10 minutes out). Our
  sunscreen successfully completed this testing and is allowed to use “Water-resistant for 80 Minutes” on its sunscreen
  label, the longest length of time allowed by the FDA.

• Claim # 3 – Unique Patented Technology / Eight-Hour Photostability:
  As previously announced, we were granted a patent from the United States Patent and Trademark Office entitled “Sunscreen
  Composition with Enhanced UVA Absorber Stability and Methods”, which provides protection until November 2029. Skinvisible
  successfully formulated a unique Invisicare® delivery system specifically for stabilizing avobenzone; the key sunscreen used
  in the USA. Data submitted to the US patent office proved that our sunscreen provides a minimum of eight hours of photostability.

Additional Skinvisible Products

Sunless Tanning Products

We have developed a sunless tanning mousse / foam which uses a unique
foam with Invisicare®, developed specifically for its foaming properties. This adds to Skinvisible’s line of sunless
tanning products which includes sunless tanning lotions (light, medium and dark), pre-sun moisturizer and after-sun moisturizer
along with sunless tanning spray products for commercial use. The addition of a sunless tanning mousse enhances this line of products.

Sunscreen Products

We have developed 3 broad spectrum sunscreens, with SPF 15, 30 and
50 (the highest SPF allowed by the FDA). All are formulated with Avobenzone, the only UVA sun filter allowed under the US FDA monograph.
This UVA/UVB sunscreen was granted a patent from the United States patent office in 2013. Avobenzone is known for breaking down
in the sun after only two hours – thus the requirement to reapply every 2 hours. Skinvisible’s patent was granted based
on Invisicare’s® minimum 8 hour photo stability. For countries outside the United States, Skinvisible has additionally patented
UVA/UVB sunscreens formulated with Tinosorb S.

Capitalize On Current Licensees:

We continue to work diligently with our licensees to ensure they
have a smooth manufacturing process, ongoing R&D support and marketing feedback.

Ovation Science Inc.

On February 3, 2020, we entered into a License
Agreement with Ovation Science Inc. pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture
and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay
to Skinvisible a single digit royalty interest on all net sales on the licensed products subject to adjustment in certain situations plus
a license fee payable in year 3 of the agreement if it chooses to continue the license.

Women’s Choice Pharmaceuticals

Product: ProCort®, long lasting prescription hemorrhoid cream
launched in the United States August 2011.

Sales and Royalties: Skinvisible receives a royalty based on net
sales of ProCort. Women’s Choice has been successfully growing their sales of ProCort®

Increasing The Value of Skinvisible’s Pipeline:

We have a pipeline of over forty products which are available for
licensing. Testing is conducted in-house generating proof of concept including release of the active ingredient as well as long
term shelf life (stability). Additional studies conducted on specific products including skin sensitivity, toxicity and product
efficacy are outsourced to FDA compliant laboratories. These studies are critical in attracting potential licensees. Our clinical
strategy is to find a partner for our prescription product portfolio. This would allow for a partner to seek FDA approval using
the 505b2 pathway for one or more of our products.

Competition

Market research indicates there is reasonably limited direct
competition for Invisicare and patented products in terms of performance capabilities for topically administered skin products.
Many companies are seeking unique delivery systems to enhance their portfolio and purchasing companies that have delivery technology.

Government Regulation

Cosmetic and Skin Care Regulation

Depending upon product claims and formulation, skin care products
may be regulated as cosmetics, drugs, devices, or combination cosmetics and drugs. The FDA has authority to regulate cosmetics
marketed in the United States under the FDCA and the Fair Packaging and Labeling Act (“FPLA”) and implementing regulations.
The Federal Trade Commission (the “FTC”) regulates the advertising of cosmetics under the FTCA.

The FDCA prohibits the marketing of adulterated and misbranded cosmetics.
Cosmetic ingredients must also comply with the FDA’s ingredient, quality, and labeling requirements and the FTC’s requirements
pertaining to truthful and non-misleading advertising. Cosmetic products and ingredients, with the exception of color additives,
are not required to have FDA premarket approval. Manufacturers of cosmetics are also not required to register their establishments,
file data on ingredients, or report cosmetic-related injuries to the FDA.

We will be responsible for substantiating the safety and product
claims of the cosmetic products and ingredients before marketing. The FDA or FTC may disagree with our characterization of one
or more of the skin care products as a cosmetic or the product claims. This could result in a variety of enforcement actions which
could require the reformulation or relabeling of our products, the submission of information in support of the product claims or
the safety and effectiveness of our products, or more punitive action, all of which could have a material adverse effect on our
business. If the FDA determines we have failed to comply with applicable requirements under the FDCA or FPLA, it can impose a variety
of enforcement actions from public warning letters, injunctions, consent decrees, and civil penalties to seizure of our products,
total or partial shutdown of our production, and criminal prosecutions. If any of these events were to occur, it could materially
adversely affect us. If the FTC determines we have failed to substantiate our claims, it can pursue a variety of actions including
disgorgement of profits, injunction from further violative conduct, and consent decrees.

Domestic State and Local Government Regulation

Some states and local governments in the United States regulate
the labeling, operation, sale, and distribution of our skin care products. To the extent additional state or local laws apply,
we intend to comply with them.

Foreign Government Regulation

In general, we will need to comply with the government regulations
of each individual country in which our products are to be distributed and sold. These regulations vary in complexity and can be
as stringent, and on occasion even more stringent, than FDA regulations in the United States. The level of complexity and stringency
is not always precisely understood today for each country, creating greater uncertainty for the international regulatory process.
Furthermore, government regulations can change with little to no notice and may result in up-regulation of our product(s), thereby
creating a greater regulatory burden for us. We have not yet thoroughly explored the applicable laws and regulations that we will
need to comply with in foreign jurisdictions. As a result it is possible that we may not be permitted to sell our products in foreign
markets or expand our business into one or more foreign jurisdictions.

Environmental Laws

We are not subject to any significant or material environmental
regulation in the normal operation of our business.

Employees

Currently, we have two employees, including our CEO Terry Howlett.

Subsidiaries

We conduct our operations through our wholly-owned subsidiary, Skinvisible
Pharmaceuticals, Inc.

Risk Factors Associated with Covid 19

The extent to which the coronavirus (“COVID-19”)
outbreak impacts our business, results of operations and financial condition will depend on future developments, which cannot be
predicted.

The COVID-19 pandemic has caused us to modify our business practices
(including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences),
and we may take further actions as may be required by government authorities or that we determine are in the best interests of
our employees, customers and business partners. There is no certainty that such measures will be sufficient to mitigate the risks
posed by the virus or otherwise be satisfactory to government authorities.

The extent to which COVID-19 impacts our business, results of operations
and financial condition will depend on future developments, which are uncertain and cannot be predicted, including, but not limited
to:

Even after the coronavirus outbreak has subsided, we may continue
to experience materially adverse impacts to our business as a result of its global economic impact, including any recession that
has occurred or may occur in the future.

Risks Related to Our Financial Condition and our Business

Our investors may lose their entire investment because our
financial status creates a doubt whether we will continue as a going concern.

We do not have sufficient
cash nor do we have a significant source of revenues to cover our operational costs and allow us to continue as a going concern.  The
Company anticipates generating revenues through the licensing of its core products and if that is not sufficient we may seek to
raise additional operating capital to implement our business plan in an offering of our common stock or debt.  Our company’s
plan specifies a minimum amount of $500,000 in additional operating capital to operate for the next twelve months. However, there
can be no assurance that the revenues generated or that such an offering will be successful. You may lose your entire investment

Our failure to raise
additional capital or generate cash flows necessary to expand our operations could reduce our ability to compete successfully and
adversely affect our results of operations.

We need to raise additional
funds to achieve our future strategic objectives, and we may not be able to obtain additional debt or equity financing on favorable
terms, if at all. If we engage in debt financing, we may be required to accept terms that restrict our ability to incur additional
indebtedness, force us to maintain specified liquidity or other ratios or restrict our ability to pay dividends or make acquisitions.
If we need additional capital and cannot raise it on acceptable terms, we may not be able to, among other things:

§ 
launch, develop and enhance
our existing products;

§ 
continue to expand our
product base, sales and/or marketing efforts;

§ 
hire, train and retain
employees; or

§ 
respond to competitive
pressures or unanticipated working capital requirements.

Our inability to do any of
the foregoing could reduce our ability to compete successfully and adversely affect our results of operations.

If we are unable to generate revenues by implementing our
business plan, you will lose your entire investment in our company.

We have a history of losses from inception and we had an accumulated
deficit as of December 31, 2020 of $34,700,408. We have not been able to generate sufficient revenues from licensees, from the
sale of our own products or otherwise to cover our expenses. If we are unsuccessful in generating revenues, you could lose your
entire investment.

If our products are not deemed desirable and suitable for
purchase and we cannot establish a customer base, we may not be able to generate sufficient revenues, which would result in a failure
of the business and a loss of any investment one makes in our company.

The acceptance of our products is critically important to our success.
We cannot be certain that the products that we will be offering will be appealing and as a result there may not be any demand for
these products and our sales could be limited and we may never realize any significant revenues. In addition, there are no assurances
that if we alter or change the products we offer in the future that the demand for these new products will develop and this could
adversely affect our business and any possible revenues.

If demand for the products that we plan to offer slows, then
our business would be materially affected.

Demand for products, which we intend to sell, depends on many factors,
including:

For the long term, demand for the products we plan to offer may
be affected by:

All of these factors could result in immediate and longer term declines
in the demand for the products that we plan to offer, which could adversely affect our sales, cash flows and overall financial
condition.

Because we are new in the marketplace, we may not be able
to compete effectively and increase market share.

Our current and potential competitors may have longer operating
histories, significantly greater resources and name recognition, and a larger base of customers than we have. Our competitors may
also be able to adopt more aggressive pricing policies and devote greater resources to the development, marketing and sale of their
products and services than we can. To be competitive, we must continue to invest significant resources in sales and marketing.
We may not have sufficient resources to make these investments or to develop the technological advances necessary to be competitive,
which in turn will cause our business to suffer and restrict our profitability potential.

Because we rely on third parties to manufacture our products,
we are subject to factors outside of our control to meet our standards or timelines.

Our products are manufactured by three third-party manufacturing
companies on a purchase order basis. No contractual arrangement are currently in place, except for standard confidentiality agreements.
We are dependent on the timeliness and effectiveness of our third-part manufacturers’ efforts.

Failure or lack of reliability in the manufacture of our products
is likely to result in loss of business. Among other risks:

Like other retailers, distributors and manufacturers of skin
care and personal care products, we face an inherent risk of exposure to product liability claims in the event that the use of
the products that we sell results in injury.

We may be subjected to various product liability claims, including
claims that the products we sell contain contaminants, are improperly labeled or include inadequate instructions as to use or inadequate
warnings concerning side effects and interactions with other substances. In addition, we may be forced to defend lawsuits. We cannot
predict whether product liability claims will be brought against us in the future or the effect of any resulting adverse publicity
on the business. Moreover, we may not have adequate resources in the event of a successful claim against us. The successful assertion
of product liability claim against us could result in potentially significant monetary damages. In addition, interactions of the
products with other similar products, prescription medicines and over-the-counter drugs have not been fully explored.

We may also be exposed to claims relating to product advertising
or product quality. People may purchase our products expecting certain physical results, unique to skin care and personal care
products. If they do not perceive expected results to occur, certain individuals or groups of individuals may seek monetary retribution.

If our products become contaminated, our business could be
seriously harmed.

We have adopted various quality, environmental, health and safety
standards. However, our products may still not meet these standards or could otherwise become contaminated. A failure to meet these
standards or contamination could occur in our operations or those of our bottlers, manufacturers, distributors or suppliers. Such
a failure or contamination could result in expensive production interruptions, recalls and liability claims. Moreover, negative
publicity could be generated even from false, unfounded or nominal liability claims or limited recalls. Any of these failures or
occurrences could negatively affect our business and financial performance.

Our business may be adversely affected by unfavorable publicity
within the skin care markets.

Management believes that the skin care market and personal care
markets are significantly affected by national media attention. As with any retail provider, future scientific research or publicity
may not be favorable to the industry or to any particular product, and may not be consistent with earlier favorable research or
publicity. Because of our dependence on consumers’ perceptions, adverse publicity associated with illness or other adverse
effects resulting from the use of our products or any similar products distributed by other companies and future reports of research
that are perceived as less favorable or that question earlier research, could have a material adverse effect on our business, financial
condition and results of operations. We are highly dependent upon consumers’ perceptions of the safety and quality of the
products as well as similar products distributed by other companies. Thus, the mere publication of reports asserting that skin
care or personal care products may be harmful or questioning their efficacy could have a material adverse effect on our business,
financial condition and results of operations, regardless of whether such reports are scientifically supported or whether the claimed
harmful effects would be present at the dosages recommended for such products.

As we intend to conduct international business transactions,
we will be exposed to local business risks in different countries, which could have a material adverse effect on our financial
condition or results of operations.

We intend to promote and sell our products internationally. Our
international operations will be subject to risks inherent in doing business in foreign countries, including, but not necessarily
limited to:

We may not be successful in developing and implementing policies
and strategies to address the foregoing factors in a timely and effective manner in the locations where we will do business. Consequently,
the occurrence of one or more of the foregoing factors could have a material adverse effect on our base operations and upon our
financial condition and results of operations.

Since our products will be available over the Internet in foreign
countries and we plan to have customers residing in foreign countries, foreign jurisdictions may require us to qualify to do business
in their country. We will be required to comply with certain laws and regulations of each country in which we conduct business,
including laws and regulations currently in place or which may be enacted related to Internet services available to the residents
of each country from online sites located elsewhere.

Because of the nature of our products, we may be subject to
government regulations or laws that increase our costs of operations or decrease our ability to generate income.

Any failure by us, or by any third party that may manufacture or
market our products, to comply with the law, including statutes and regulations administered by the FDA or other U.S. or foreign
regulatory authorities, could result in, among other things, warning letters, fines and other civil penalties, suspension of regulatory
approvals and the resulting requirement that we suspend sales of our products, refusal to approve pending applications or supplements
to approved applications, export or import restrictions, interruption of production, operating restrictions, closure of the facilities
used by us or third parties to manufacture our product candidates, injunctions or criminal prosecution. Any of the foregoing actions
could have a material adverse effect on our business.

Our commercial success depends significantly on our ability
to develop and commercialize our potential products without infringing the intellectual property rights of third parties.

Our commercial success will depend, in part, on operating our business
without infringing the patents or proprietary rights of third parties. Third parties that believe we are infringing on their rights
could bring actions against us claiming damages and seeking to enjoin the development, marketing and distribution of our products.
If we become involved in any litigation, it could consume a substantial portion of our resources, regardless of the outcome of
the litigation. If any of these actions are successful, we could be required to pay damages and/or to obtain a license to continue
to develop or market our products, in which case we may be required to pay substantial royalties. However, any such license may
not be available on terms acceptable to us or at all. Ultimately, we could be prevented from commercializing a product or forced
to cease some aspect of our business operations as a result of patent infringement claims, which would harm our business.

The implementation of our business plan relies on our ability
to manage growth. If we are not able to manage the growth, our business plan may not be successfully implemented.

We expect to expand our operations by increasing our sales and marketing
efforts, research and development activities, and escalating our services. The anticipated growth could place a significant strain
on our management, and operational and financial resources. Effective management of the anticipated growth shall require expanding
our management and financial controls, hiring additional appropriate personnel as required, and developing additional expertise
by existing management personnel. However, there can be no assurances that these or other measures we may implement shall effectively
increase our capabilities to manage such anticipated growth or to do so in a timely and cost-effective manner. Moreover, management
of growth is especially challenging for a company with a short revenue generating history and limited financial resources, and
the failure to effectively manage growth could have a material adverse effect on our operations.

Our success depends on continuing to hire and retain qualified
personnel, including our director and officers and our technical personnel.  If we are not successful in attracting and retaining
these personnel, our business will suffer.

Our success depends substantially on the performance
of our management team and key personnel. Currently, we have three employees, including our CEO Terry Howlett. Due to the specialized
technical nature of our business, we are particularly dependent on our technical personnel. Our future success will depend on our
ability to attract, integrate, motivate and retain qualified technical, sales, operations, and managerial personnel, as well as
our ability to successfully implement a plan for management succession. Competition for qualified personnel in our business areas
is intense, and we may not be able to continue to attract and retain key personnel. In addition, if we lose the services of any
of our management team or key personnel and are not able to find suitable replacements in a timely manner, our business could be
disrupted and we may incur increased operating expenses.

 If
we are unable to attract new distributors and customers, or if our existing
distributors and customers do not purchase additional products, the growth of our
business and cash flows will be adversely affected.

To increase
our revenues and cash flows, we must regularly add distributors and customers and
sell additional products to our existing distributors and customers. If we are unable
to sell our products to customers that have been referred to us, unable to generate sufficient sales leads through our marketing
programs, or if our existing or new distributors and customers do not perceive our
products to be of sufficiently high value and quality, we may not be able to increase sales and our operating results would be
adversely affected. In addition, if we fail to sell new products to existing distributors and customers or
new distributors and customers, our operating results will suffer, and our revenue
growth, cash flows and profitability may be materially and adversely affected.

Key management personnel may leave us, which could adversely
affect our ability to continue operations.

We are entirely dependent on the efforts of our management because
of the time and effort that they devote to us. They are in charge of overseeing all development strategies, supervising any/all
future personnel, and the implementation of our business plan. Their loss, or other key personnel in the future, could have a material
adverse effect on our business, financial condition and results of operations.

Risks Related to Our Securities

If a market for our common stock does not develop, shareholders
may be unable to sell their shares.

Our common stock is quoted under the symbol “SKVI” on
the OTCQB operated by OTC Markets Group, Inc, an electronic inter-dealer quotation medium for equity securities. We do not currently
have an active trading market. There can be no assurance that an active and liquid trading market will develop or, if developed,
that it will be sustained.

Our securities are very thinly traded. Accordingly, it may be difficult
to sell shares of our common stock without significantly depressing the value of the stock. Unless we are successful in developing
continued investor interest in our stock, sales of our stock could continue to result in major fluctuations in the price of the
stock.

Our common stock price may be volatile and could fluctuate
widely in price, which could result in substantial losses for investors.

The market price of our common stock is likely to be highly volatile
and could fluctuate widely in price in response to various factors, many of which are beyond our control, including:

• technological innovations or new products and services by us or
  our competitors;
• government regulation of our products and services;
• the establishment of partnerships with other technology companies;
• intellectual property disputes;
• additions or departures of key personnel;
• sales of our common stock
• our ability to integrate operations, technology, products and services;
• our ability to execute our business plan;
• operating results below expectations;
• loss of any strategic relationship;
• industry developments;
• economic and other external factors; and
• period to period fluctuations in our financial results.

Because we have nominal revenues to date, you should consider any
one of these factors to be material. Our stock price may fluctuate widely as a result of any of the above.

In addition, the securities markets have from time to time experienced
significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market
fluctuations may also materially and adversely affect the market price of our common stock.

We have not paid cash dividends in the past and do not expect
to pay cash dividends in the future on our common stock. Any return on investment may be limited to the value of our common stock.

We have never paid cash dividends on our common stock and do not
anticipate paying cash dividends in the foreseeable future. The payment of cash dividends on our common stock will depend on earnings,
financial condition and other business and economic factors at such time as the board of directors may consider relevant. If we
do not pay cash dividends, our common stock may be less valuable because a return on your investment will only occur if its stock
price appreciates.

As a new investor, you will experience substantial dilution
as a result of future equity issuances.

In the event we are required to raise additional capital it may
do so by selling additional shares of common stock thereby diluting the shares and ownership interests of existing shareholders.

Because we are subject to the “Penny Stock” rules,
the level of trading activity in our stock may be reduced.

The Securities and Exchange Commission has adopted regulations which
generally define “penny stock” to be any listed, trading equity security that has a market price less than $5.00 per
share or an exercise price of less than $5.00 per share, subject to certain exemptions. The penny stock rules require a broker-dealer,
prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document
that provides information about penny stocks and the risks in the penny stock market. The broker-dealer must also provide the customer
with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction,
and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition,
the penny stock rules generally require that prior to a transaction in a penny stock, the broker-dealer make a special written
determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement
to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary
market for a stock that becomes subject to the penny stock rules which may increase the difficulty Purchasers may experience in
attempting to liquidate such securities.

Provisions in the Nevada Revised Statutes and our Bylaws could
make it very difficult for an investor to bring any legal actions against our directors or officers for violations of their fiduciary
duties or could require us to pay any amounts incurred by our directors or officers in any such actions.

Members of our board of directors and our officers will have no
liability for breaches of their fiduciary duty of care as a director or officer, except in limited circumstances, pursuant to provisions
in the Nevada Revised Statutes and our Bylaws as authorized by the Nevada Revised Statutes. Specifically, Section 78.138 of the
Nevada Revised Statutes provides that a director or officer is not individually liable to the company or its shareholders or creditors
for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that
(1) the director’s or officer’s act or failure to act constituted a breach of his or her fiduciary duties as a director
or officer and (2) his or her breach of those duties involved intentional misconduct, fraud or a knowing violation of law. This
provision is intended to afford directors and officers protection against and to limit their potential liability for monetary damages
resulting from suits alleging a breach of the duty of care by a director or officer. Accordingly, you may be unable to prevail
in a legal action against our directors or officers even if they have breached their fiduciary duty of care. In addition, our Bylaws
allow us to indemnify our directors and officers from and against any and all costs, charges and expenses resulting from their
acting in such capacities with us. This means that if you were able to enforce an action against our directors or officers, in
all likelihood, we would be required to pay any expenses they incurred in defending the lawsuit and any judgment or settlement
they otherwise would be required to pay. Accordingly, our indemnification obligations could divert needed financial resources and
may adversely affect our business, financial condition, results of operations and cash flows, and adversely affect prevailing market
prices for our common stock.

Currently, we do not own any or lease any real estate.

Item 3. Legal Proceedings

We are not a party to any pending
legal proceeding. We are not aware of any pending legal proceeding to which any of our officers, directors, or any beneficial holders
of 5{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} or more of our voting securities are adverse to us or have a material interest adverse to us.

Not Applicable

PART
II

Market Information

Our common stock is quoted under the symbol
“SKVI” on the OTCQB operated by OTC Markets Group, Inc. 

The OTCQB is a quotation service that displays
real-time quotes, last-sale prices, and volume information in over-the-counter equity securities. An OTCQB equity security generally
is any equity that is not listed or traded on a national securities exchange. Because we are quoted on the OTCQB, our securities
may be less liquid, receive less coverage by security analysts and news media, and generate lower prices than might otherwise be
obtained if they were listed on a national securities exchange.

Trading in stocks quoted on the OTCQB is often
thin and is characterized by wide fluctuations in trading prices due to many factors that may be unrelated to a company’s
operations or business prospects. We cannot assure you that there will be a market in the future for our common stock.

Penny Stock

The SEC has adopted rules that regulate broker-dealer practices
in connection with transactions in penny stocks. Penny stocks are generally equity securities with a market price of less than
$5.00, other than securities registered on certain national securities exchanges or quoted on the NASDAQ system, provided that
current price and volume information with respect to transactions in such securities is provided by the exchange or system. The
penny stock rules require a broker-dealer, prior to a transaction in a penny stock, to deliver a standardized risk disclosure document
prepared by the SEC, that: (a) contains a description of the nature and level of risk in the market for penny stocks in both public
offerings and secondary trading; (b) contains a description of the broker’s or dealer’s duties to the customer and
of the rights and remedies available to the customer with respect to a violation of such duties or other requirements of the securities
laws; (c) contains a brief, clear, narrative description of a dealer market, including bid and ask prices for penny stocks and
the significance of the spread between the bid and ask price; (d) contains a toll-free telephone number for inquiries on disciplinary
actions; (e) defines significant terms in the disclosure document or in the conduct of trading in penny stocks; and (f) contains
such other information and is in such form, including language, type size and format, as the SEC shall require by rule or regulation.

The broker-dealer also must provide, prior to effecting any transaction
in a penny stock, the customer with (a) bid and offer quotations for the penny stock; (b) the compensation of the broker-dealer
and its salesperson in the transaction; (c) the number of shares to which such bid and ask prices apply, or other comparable information
relating to the depth and liquidity of the market for such stock; and (d) a monthly account statement showing the market value
of each penny stock held in the customer’s account.

In addition, the penny stock rules require that prior to a transaction
in a penny stock not otherwise exempt from those rules, the broker-dealer must make a special written determination that the penny
stock is a suitable investment for the purchaser and receive the purchaser’s written acknowledgment of the receipt of a risk
disclosure statement, a written agreement as to transactions involving penny stocks, and a signed and dated copy of a written suitability
statement.

These disclosure requirements may have the effect of reducing the
trading activity for our common stock. Therefore, stockholders may have difficulty selling our securities.

Holders of Our Common Stock

As of April 6, 2021, we had 4,539,843 shares of our common stock
issued and outstanding, held by 253 shareholders of record, other than those held in street name.

Dividends

There are no restrictions in our articles of incorporation or bylaws
that prevent us from declaring dividends. The Nevada Revised Statutes, however, do prohibit us from declaring dividends where after
giving effect to the distribution of the dividend:

We have not declared any dividends and we do not plan to declare
any dividends in the foreseeable future.

Recent Sales of Unregistered Securities

The information set forth below relates to our issuances of securities
without registration under the Securities Act of 1933 during the reporting period which were not previously included in a Quarterly
Report on Form 10-Q or Current Report on Form 8-K.

During the year ended December 31, 2020, the Company issued 68,097
shares valued at $59,602 to investors in settlement of outstanding stock payable.

These securities were issued pursuant to Section 4(2) of the Securities
Act and/or Rule 506 promulgated thereunder. The holders represented their intention to acquire the securities for investment only
and not with a view towards distribution. The investors were given adequate information about us to make an informed investment
decision. We did not engage in any general solicitation or advertising. We directed our transfer agent to issue the stock certificates
with the appropriate restrictive legend affixed to the restricted stock.

Securities Authorized for Issuance under Equity Compensation
Plans

The following table provides information about our compensation
plans under which shares of common stock may be issued upon the exercise of options as of December 31, 2020.

In July 2006, we adopted the 2006 Skinvisible, Inc. Stock Option
Plan, which provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted
stock, performance shares and performance units, and stock awards our officers, directors or employees of, as well as advisers
and consultants. This plan was confirmed by our stockholders on August 7, 2006 at the annual shareholders meeting.

Under the 2006 Skinvisible, Inc. Stock Option Plan, we reserved
200,000 shares of common stock for the granting of options and rights.

Equity Compensation
Plans as of December 31, 2020

A smaller reporting company is not required to provide the information
required by this Item.

Item 7. Management’s Discussion and Analysis of Financial
Condition and Results of Operations

Forward-Looking Statements

Certain statements, other than purely historical information, including
estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions
upon which those statements are based, are “forward-looking statements.” These forward-looking statements generally
are identified by the words “believes,” “project,” “expects,” “anticipates,” “estimates,”
“intends,” “strategy,” “plan,” “may,” “will,” “would,”
“will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking
statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual
results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future
plans or strategies is inherently uncertain. Factors which could have a material adverse affect on our operations and future prospects
on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability
of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also
be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

COVID-19

The full extent of the impact
of the COVID-19 pandemic on our business, operations and financial results will depend on numerous evolving factors that we may
not be able to accurately predict at the present time. In an effort to contain COVID-19 or slow its spread, governments around
the world have enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents
to their homes or places of residence, and practice social distancing when engaging in essential activities. We anticipate that
these actions and the global health crisis caused by COVID-19 will negatively impact business activity across the globe. While
we have not observed any noticeable impact on our revenue related to these conditions in the past fiscal year, or through the date
of this filing, we cannot estimate the impact COVID-19 will have in the future as business and consumer activity decelerates across
the globe.

We will continue to actively
monitor the situation and may take further actions that alter our business operations as may be required by federal, state, local
or foreign authorities, or that we determine are in the best interests of our employees, customers, partners and stockholders.
It is not clear what the potential effects any such alterations or modifications may have on our business, including the effects
on our customers, partners, or vendors, or on our financial results.

Results of
Operations for the Years Ended December 31, 2020 and 2019

Revenues

Our revenue from product sales, royalties on patent licenses and
license fees (product development fees) for the year ended December 31, 2020 was $275,556, an increase from $43,166 for the year
ended December 31, 2019.

The increase in revenue for year ended December 31, 2020 was mainly
due to our license agreements with Ovation and Quoin.

Cost of Revenues

Our cost of revenues for the year ended December 31, 2020 decreased
to $0 from the prior year when cost of revenues was $17,551.

Our cost of revenues decreased for the year ended December 31, 2020
over the prior year period as a result of decreased product sales and increased license fees that do not have a cost of revenue.

Gross Profit

Gross profit for the year ended December 31, 2020 was $275,556,
or 100{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of sales. Gross profit for the year ended December 31, 2019 was $25,615, or approximately 60{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of sales. Our gross profit
margin increased significantly in 2020 over 2019 as a result of the increased license fee revenue, which has no costs verses product
sales.

Operating Expenses

Operating expenses decreased
to $529,221 for the year ended December 31, 2020 from $565,392 for the year ended December 31, 2019. Our operating expenses for
the year ended December 31, 2020 consisted mainly of selling, general and administrative expenses of $497,199 and depreciation
and amortization of $32,022. In comparison, our operating expenses for the year ended December 31, 2019 consisted mainly of selling,
general and administrative expenses of $525,776 and depreciation and amortization of $39,616.

Other Expenses

We had other expense of $1,193,947 for the year ended December
31, 2020, compared with other expenses of $1,162,354 for the year ended December 31, 2019. Our other expenses for 2020 are the
result of interest expense. Our other expenses for 2019 is largely the result of $1,004,756 in interest expense and $247,998 in
the extinguishment of debt offset by $90,400 as other related party income.

We expect to experience high debt payments in the future
as a result of our outstanding liabilities. Moreover, as of the date of this report, there are a number of secured promissory notes
with an aggregate principal amount of approximately $762,000 that have matured. In addition, we also have one unsecured promissory
note with an aggregate principal amount of $10,000 that has matured. If we are unable to generate sufficient revenues and/or additional
financing to service this debt, there is a risk the lenders will call the notes, secure our assets, as to those applicable secured
notes, and demand payment. If this happens, we could go out of business.

Net Loss

We recorded net loss for the year ended December 31, 2020 of $1,447,612
compared to net loss of $1,702,131 for the year ended December 31, 2019.

Liquidity and
Capital Resources

Going concern –
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. The Company has incurred cumulative net losses of $34,700,408
since its inception and requires capital for its contemplated operational and marketing activities to take place. The Company’s
ability to generate the necessary funds through licensing of its core products or the ability to raise additional capital through
the future issuances of common stock or debt is unknown. The obtainment of additional financing, the successful development of
the Company’s contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations
are necessary for the Company to continue operations. These factors, among others, raises substantial doubt about the Company’s
ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that
may result from the outcome of these aforementioned uncertainties.

As of December 31, 2020, we had total current assets of $50,114
and total assets in the amount of $200,244. Our total current liabilities as of December 31, 2020 were $2,718,985. We had a working
capital deficit of $ 2,668,871 as of December 31, 2020 as compared with a working capital deficit of $2,550,568 as of September
30, 2020 and a working capital deficit of $1,900,688 as of December 31, 2019. The change in working capital is largely the result
of our efforts to convert debt into equity during the year.

Operating activities used $45,765 in cash for the year ended December
31, 2020, as compared with $128,212 for the year ended December 31, 2019. The company’s net loss was the main component of
our negative operating cash flow, offset mainly by an increase in accrued interest of $529,772 amortization of debt discount of
$664,174 and an increase in accounts payable and accrued liabilities of $268,206.

Cash flows used by investing activities during the year ended December
31, 2020 was $16,767 as compared with $26,116 for the year ended December 31, 2019, as a result of the purchase of intangible assets
for 2019 and 2018.

Cash flows provided by financing activities during the year ended
December 31, 2020 amounted to $5,600 as compared with $78,144 for the year ended December 31, 2019. Cash flows for the year ended
December 31, 2020 consisted of $26,900 in proceeds from related party debt offset by $21,300 paid on notes payable. Cash flows
for the year ended December 31, 2019 mainly consisted of $117,144 in proceeds from related party debt, offset by $39,000 in payments
on notes payable.

Based upon our current financial
condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to
fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures
or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations.
There can be no assurance that we will be successful in raising additional funding. If we are not able to secure additional funding,
the implementation of our business plan will be impaired. There can be no assurance that such additional financing will be available
to us on acceptable terms or at all. 

Off
Balance Sheet Arrangements

As
of December 31, 2020, there were no off balance sheet arrangements.

Critical Accounting Policies

In December 2001, the SEC
requested that all registrants list their most “critical accounting polices” in the Management Discussion and Analysis.
The SEC indicated that a “critical accounting policy” is one which is both important to the portrayal of a company’s
financial condition and results, and requires management’s most difficult, subjective or complex judgments, often as a result
of the need to make estimates about the effect of matters that are inherently uncertain.

Product sales –
Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products are transferred to the
customer and only when no further contingencies or material performance obligations are warranted, and thereby have earned the
right to receive reasonably assured payments for products sold and delivered.

Royalty sales –
We also recognize royalty revenue from licensing our patented product formulations only when earned, with no further contingencies
or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured payments.

Distribution and license
rights sales – We also recognize revenue from distribution and license rights only when earned (and are amortized over
a five-year period), with no further contingencies or material performance obligations are warranted, and thereby have earned the
right to receive and retain reasonably assured payments.

Costs of Revenue –
Cost of revenue includes raw materials, component parts, and shipping supplies. Shipping and handling costs is not a significant
portion of the cost of revenue.

Accounts Receivable
– Accounts receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment
within 30 days from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If
management determines that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that
will not be collected is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date
and, based on an assessment of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of
December 31, 2020, the Company had not recorded a reserve for doubtful accounts. The Company has $175,000 in convertible notes
payable which are secured by the accounts receivable of a license agreement the Company has with Women’s Choice Pharmaceuticals,
LLC on its proprietary prescription product, ProCort®.

Recently Issued Accounting
Pronouncements

We do not expect the adoption
of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position or cash
flow.

A smaller reporting company
is not required to provide the information required by this Item.

Index
to Financial Statements Required by Article 8 of Regulation S-X:

Audited Financial Statements:

REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM

To the Board of Directors and
Stockholders of Skinvisible, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance
sheets of Skinvisible, Inc. (the Company) as of December 31, 2020 and 2019, and the related statements of operations, stockholders’
deficit, and cash flows for each of the years in the two-year period ended December 31, 2020, and the related notes (collectively
referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each
of the years in the two-year period ended December 31, 2020, in conformity with accounting principles generally accepted in the
United States of America.

Going Concern

The accompanying financial statements have been
prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company
has incurred cumulative net losses, which raises substantial doubt about its ability to continue as a going concern. Management’s
plans concerning these matters are also described in Note 2. The financial statements do not include any adjustments that might
result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility
of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the
effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated
below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated
to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved
our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any
way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below,
providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Revenue Recognition

As described in Note 3, to the financial
statements, the Company recognizes revenue when title to the products are transferred to the customer and only when no further
contingencies or material performance obligations are warranted, and thereby have earned the right to receive reasonably assured
payments for products sold and delivered.

The principal considerations for our determination
that performing procedures relating to revenue recognition as a critical audit matter are the significant judgement by management
in determining the nature, timing and extent in the recognition of revenue, this in turn led to significant auditor judgement,
subjectivity, and effort in performing procedures and evaluating audit evidence.

Addressing the matter involved performing
procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures
included: 1) evaluating the appropriateness and consistency of management’s methods and assumptions used in identification,
recognition, measurement and disclosure of revenue 2) reading contract source documents for each audit selection, including master
agreements, and other documents that were part of the agreement 3) testing management’s identification and treatment of contract
terms 4) Assessing the terms in the customer agreement and evaluated the appropriateness of management’s application of their
accounting policies, along with their use of estimates, in the determination of revenue recognition conclusions 5) testing the
mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the financial
statements.

Valuation of Intangible Assets

As disclosed in Note 6, to the financial
statements, intangible assets are tested for impairment at least annually and has determined that no impairment write-down is considered
necessary as of December 31, 2020. Auditing management’s impairment tests of intangible assets was complex and highly judgmental
due to the significant measurement uncertainty in determining the fair values of intangible assets.

The principal considerations for our determination
that performing procedures relating to the valuation of intangible assets as a critical audit matter are the significant judgement
by management in determining the nature, timing and extent of the carrying value of intangible assets, this in turn led to significant
auditor judgement, subjectivity, and effort in performing procedures and evaluating audit evidence.

Addressing the matter included assessing
methodologies and testing the significant assumptions and underlying data used by the Company. We compared the significant assumptions
used in the Company’s plan for the next twelve months, as well as revenue and operating margins, to current industry and
economic trends, including the impact of COVID-19.

SKINVISIBLE,
INC.

CONSOLIDATED
BALANCE SHEETS

See
Accompanying Notes to Consolidated Financial Statements.  

SKINVISIBLE,
INC.

CONSOLIDATED
STATEMENTS OF OPERATIONS 

See
Accompanying Notes to Consolidated Financial Statements.

SKINVISIBLE,
INC.

CONSOLIDATED
STATEMENT OF STOCKHOLDERS’ DEFICIT

See
Accompanying Notes to Consolidated Financial Statements.

SKINVISIBLE,
INC.

CONSOLIDATED
STATEMENTS OF CASH FLOWS

See
Accompanying Notes to Consolidated Financial Statements.

SKINVISIBLE,
INC.

NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS

1.       DESCRIPTION
OF BUSINESS AND HISTORY

Description
of business – Skinvisible, Inc., (referred to as the “Company”) is focused on the development, manufacture
and sales of innovative topical, transdermal and mucosal polymer-based delivery system technologies and formulations incorporating
its patent-pending formula/process for combining hydrophilic and hydrophobic polymer emulsions. The technologies and formulations
have broad industry applications within the pharmaceutical, over-the-counter, personal skincare and cosmetic arenas. Additionally,
the Company’s non-dermatological formulations offer solutions for a broad spectrum of markets including women’s health,
pain management, and others. The Company maintains executive and sales offices in Las Vegas, Nevada.

History
– The Company was incorporated in Nevada on March 6, 1998, under the name of Microbial Solutions, Inc. The Company underwent
a name change on February 26, 1999, when it changed its name to Skinvisible, Inc. The Company’s subsidiary’s name
of Manloe Labs, Inc. was also changed to Skinvisible Pharmaceuticals, Inc.

Skinvisible,
Inc., together with its subsidiaries, shall herein be collectively referred to as the “Company.”

2.       BASIS
OF PRESENTATION AND GOING CONCERN

Basis of presentation – The accompanying
audited financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the
United States of America. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary
for a fair presentation of financial position and the results of operations for the period presented have been reflected herein.

Going concern –   The
accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and
the satisfaction of liabilities in the normal course of business. For the year ended December 31, 2020, the Company had
a net loss of $1,447,612 The Company has also incurred cumulative net losses of $34,700,408 since its inception and requires capital
for its contemplated operational and marketing activities to take place. These factors, among others, raises substantial doubt
about the Company’s ability to continue as a going concern within one year from the date of filing. Managements plans for
the Company are to generate the necessary funding through licensing of its core products
and to seek additional debt and equity funding. However, the Company’s ability to generate the necessary funds through
licensing or raise additional capital through the future issuances of common stock or debt is unknown. The obtainment of additional
financing, the successful development of the Company’s contemplated plan of operations, and its transition, ultimately, to
the attainment of profitable operations are necessary for the Company to continue operations. The consolidated financial statements
of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

The Company’s operations and business have
experienced disruption due to the unprecedented conditions surrounding the COVID-19 pandemic spreading throughout the United States
and elsewhere. The spread of COVID-19 has caused a change in the availability of our staff and support services. Due to the COVID-19
pandemic, there has been uncertainty and disruption in the global economy and financial markets. The Company is not aware of any
specific event or circumstance that would require an update to its estimates or judgments or a revision of the carrying value of
its assets or liabilities as of the date of issuance of this filing. These estimates could change in the future, as new events
occur, or additional information is obtained. 

3.       SUMMARY
OF SIGNIFICANT POLICIES

This summary of significant accounting
policies of Skinvisible Inc. is presented to assist in understanding the Company’s consolidated financial statements. The
consolidated financial statements and notes are representations of the Company’s management, who
are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally
accepted in the United States of America and have been consistently applied in the preparation of the consolidated financial statements.  

Principles of consolidation –
The consolidated financial statements include the accounts of the Company and its subsidiary Skinvisible Pharmaceuticals Inc. All
significant intercompany balances and transactions have been eliminated.

Use
of estimates – The preparation of consolidated financial statements in conformity with accounting principles generally
accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements,
and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates include estimates used to review the Company’s impairments and estimations of long-lived assets, allowances
for uncollectible accounts, inventory valuation, and the valuations of non-cash capital stock issuances. The Company bases its
estimates on historical experience and on various other assumptions that are believed to be reasonable in the circumstances, the
results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Cash and cash equivalents – For
purposes of the statement of cash flows, the Company considers all highly liquid investments and short-term instruments with original
maturities of three months or less to be cash equivalents.

Fair
Value of financial instruments –The carrying value of cash, accounts payable and accrued expenses, and debt (See Notes
6 & 8) approximate their fair values because of the short-term nature of these instruments. Management believes the Company
is not exposed to significant interest or credit risks arising from these financial instruments. The carrying amount of the Company’s
convertible debt is also stated at a fair value of $4,807,284 since the stated rate of interest approximates market rates.

Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in
the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on
the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use
of unobservable inputs. The Company utilizes a fair value hierarchy based on three levels of inputs, of which the first two are
considered observable and the last unobservable.

Revenue recognition – We recognize
revenue in accordance with generally accepted accounting principles as outlined in the Financial Accounting Standard Board’s (“FASB”)
Accounting Standards Codification (“ASC”) 606, Revenue From Contracts with Customers, which requires that five steps
be followed in evaluating revenue recognition: (i) identify the contract with the customer; (ii) identify the performance obligations
in the contract; (iii) determine the transaction price; (iv) allocate the transaction price; and (v) recognize revenue when or
as the entity satisfied a performance obligation.

Product
sales – Revenues from the sale of products (Invisicare® polymers) are recognized when title to the products
are transferred to the customer and only when no further contingencies or material performance obligations are warranted, and
thereby have earned the right to receive reasonably assured payments for products sold and delivered.

Royalty
sales – We also recognize royalty revenue from licensing our patented product formulations only when earned, with
no further contingencies or material performance obligations are warranted, and thereby have earned the right to receive and retain
reasonably assured payments.

Distribution
and license rights sales – We also recognize revenue from distribution and license rights when no further contingencies
or material performance obligations are warranted, and thereby have earned the right to receive and retain reasonably assured
payments.

The
Company has made an accounting policy election to exclude from the measurement of the transaction price all taxes assessed by
governmental authorities that are collected by the Company from its customers (sales and use taxes, value added taxes, some excise
taxes).

Accounts Receivable – Accounts
receivable is comprised of uncollateralized customer obligations due under normal trade terms requiring payment within 30 days
from the invoice date. The carrying amount of accounts receivable is reviewed periodically for collectability. If management determines
that collection is unlikely, an allowance that reflects management’s best estimate of the amounts that will not be collected
is recorded. Management reviews each accounts receivable balance that exceeds 30 days from the invoice date and, based on an assessment
of creditworthiness, estimates the portion, if any, of the balance that will not be collected. As of December 31, 2020 and 2019,
the Company had determined it was not necessary to recognize a reserve for doubtful accounts.

Intangible
assets – The Company follows Financial Accounting Standard Board’s (FASB) Codification Topic 350-10 (“ASC
350-10”), “Intangibles – Goodwill and Other”. According to this statement, intangible assets with
indefinite lives are no longer subject to amortization, but rather an annual assessment of impairment by applying a fair-value
based test.  Under ASC 350-10, the carrying value of assets are calculated at the lowest level for which there are identifiable
cash flows.

Income
taxes – The Company accounts for its income taxes in accordance with FASB Codification Topic ASC 740-10, “Income
Taxes”, which requires recognition of deferred tax assets and liabilities for future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases
and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable
income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

Stock-based
compensation – The Company follows the guidelines in FASB Codification Topic ASC 718-10 “Compensation-Stock
Compensation”, which requires the measurement and recognition of compensation expense for all share-based payment awards
made to employees and directors including employee stock options and employee stock purchases related to an Employee Stock Purchase
Plan based on the estimated fair values.

Earnings
(loss) per share – The Company reports earnings (loss) per share in accordance with FASB Codification Topic ASC 260-10
“Earnings Per Share”, Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders
by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings
(loss) per share except that the denominator is increased to include the number of additional common shares that would have been
outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings
(loss) per share has not been presented for the year ending December 31, 2020 since the effect of the assumed exercise of options
and warrants to purchase common shares (common stock equivalents) would have an anti-dilutive effect. There are 30,779,400 additional
shares issuable in connection with outstanding options, warrants, stock payable and convertible debts as of December 31, 2020.
The shares issuable under each instrument is as follows; 100,000 shares issuable for options, 60,000 shares issuable for warrants,
30,619,400 shares issuable under convertible notes. There were 25,317,929 additional shares issuable in connection with outstanding
options, warrants, stock payable and convertible debts as of December 31, 2019. The shares which were issuable at that date under
each instrument were as follows; 100,000 shares issuable for options, 72,000 shares issuable for warrants, 59,602 shares issuable
for shares payable and 25,086,327 shares issuable under convertible notes.

Recently
issued accounting pronouncements – The Company has evaluated all other recent accounting pronouncements and believes
that none of them will have a material effect on the Company’s financial position, results of operations or cash flows.

4.      
 RELATED PARTY TRANSACTIONS

During
the year ended December 31, 2020, $26,900 was advanced by an officer and $21,300 was repaid to another officer.

As
of December 31, 2020, $52,499 in advances remained due to officers of the company. All other related party notes have been extinguished
or re-negotiated as convertible notes. (See note 9 for additional details.)

License
Agreement with Ovation Science for DermSafe hand sanitizer – On February 3, 2020, we entered into a License Agreement
with Ovation Science Inc., a related party, pursuant to which Skinvisible granted to Ovation Science Inc. a license for the manufacture
and distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay
to Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus
a license fee payable in year 3 of the agreement if it chooses to continue the license.

On
June 10, 2020, Ovation Science Inc. paid
the Company the fee otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6-years
and granted Ovation additional rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and
02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange
for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the year ending December
31, 2020 and recognized $100,000 in revenue.

The
Company earned $15,860 in royalties under the license agreement during the year ending December 31, 2020.

The
Company sold polymer products to Ovation Science Inc and earned $7,132 and 0 as of December 31, 2020 and 2019, respectively.

Convertible
Notes Related Party

5.       FIXED
ASSETS

Depreciation
expense for the years ended December 31, 2020 and 2019 was $0 and $119, respectively.

During
the year ended December 31, 2019, the Company sold furniture, fixtures and lab equipment to Ovation Science, a related party,
for $75,000, the assets had been fully depreciated by the Company in prior years and the Company recorded a gain from related
party of $75,000 as a result of the sale.

6.       INTANGIBLE
AND OTHER ASSETS

Patents
and other intangible assets are capitalized at their historical cost and are amortized over their estimated useful
lives. As of December 31, 2020 intangible assets total $261,726, net of $111,596 of accumulated amortization. As of December 31,
2019, intangible assets total $698,800, net of $533,415 of accumulated amortization.

The
Company capitalized $16,767 in patent cost during the year ended December 31, 2020.

Amortization
expense for the years ended December 31, 2020 and 2019 was $34,056 and $39,497, respectively. License and distributor rights were
acquired by the Company in January 1999 and provide exclusive use distribution of polymers and polymer based products. The Company
has a non-expiring term on the license and distribution rights. Accordingly, the Company annually assesses this license and distribution
rights for impairment and has determined that no impairment write-down is considered necessary as of December 31, 2020.

7.       NOTES
PAYABLE

Secured
debt offering

During
the period from May 22, 2013 and December 31, 2018, the Company entered into a 9{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} notes payable to nineteen investors and received
proceeds of $552,000. The notes were due two years from the anniversary date of execution. The Notes are secured by the US Patent
rights granted for the Company’s Sunscreen Products: US patent number #8,128,913: “Sunscreen Composition with Enhanced UV-A
Absorber Stability and Methods.”

As
of December 31, 2020, $552,000 of the outstanding notes payable are past due and in default and have been classified as current
notes payable.

8.       CONVERTIBLE
NOTES PAYABLE

9.   
COMMITMENTS AND CONTINGENCIES

License
Agreement

On
October 17, 2019, Skinvisible entered an Exclusive License Agreement with Quoin pursuant to which Skinvisible granted to Quoin
a license to certain patents for the development of products for commercial sale. In exchange for the license, Quoin agreed to
pay to Skinvisible a license fee of $1,000,000 and a royalty percentage on all net sales on the licensed products subject to adjustment
in certain situations. The agreement also requires that Quoin make certain milestone payments to Skinvisible upon achieving regulatory
approval milestones for certain drug products.

The
agreement is subject to termination, if among other things, 50{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of the license fee is not paid by December 31, 2019 and if the
full License Fee is not paid by March 31, 2020. No payments were made by Quoin and the agreement was terminated on December 31,
2019. Both Parties subsequently determined that they continue to see the value in a partnership and therefore on May 8, 2020 and
again on July 31, 2020 the companies agreed to extend the Exclusive License Agreement, as amended under the same terms to expire
on September 30, 2020   and
on January 27, 2021 the companies agreed to revise the milestone payments due under the agreement and to extend the agreement indefinitely
(See note 13).  As of December 31, 2020 the Company has received $125,000 in licensing fee income per this agreement.

10.   
INCOME TAXES  

The
Company provides for income taxes under FASB ASC 740, Accounting for Income Taxes. FASB ASC 740 requires the use of an asset
and liability approach in accounting for income taxes. Deferred tax assets and liabilities are recorded based on the differences
between the financial statement and tax bases of assets and liabilities and the tax rates in effect currently.

FASB
ASC 740 requires the reduction of deferred tax assets by a valuation allowance, if, based on the weight of available evidence,
it is more likely than not that some or all of the deferred tax assets will not be realized. In the Company’s opinion, it
is uncertain whether they will generate sufficient taxable income in the future to fully utilize the net deferred tax asset. Accordingly,
a valuation allowance equal to the deferred tax asset has been recorded. The total deferred tax asset is approximately $3.0 million
as of December 31, 2020 which is calculated by multiplying a 21{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} estimated tax rate by the cumulative net operating loss (NOL)
of approximately $14.6 million.

Due
to the enactment of the Tax Reform Act of 2017, we have calculated our deferred tax assets using an estimated corporate tax rate
of 21{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3}. US Tax codes and laws may be subject to further reform or adjustment which may have a material impact to the Company’s
deferred tax assets and liabilities.

The
Company will recognize interest and penalties related to uncertain tax positions as a component of income tax expense. As of December
31, 2020, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized
in the Company’s statement of operations.

The
significant components of the Company’s deferred tax assets and liabilities as of December 31, 2020 and 2019 are as follows:

As
of December 31, 2020, and 2019, the Company had gross federal net operating loss carryforwards of approximately $14.6 million and
$13.2 million, respectively.

The
Company plans to file its U.S. federal return for the year ended December 31, 2020 upon the issuance of this filing. Upon filing
of the tax return for the year ended December 31, 2019 the actual deferred tax asset and associated valuation allowance available
to the Company may differ from management’s estimates. The tax years 2017-2019 remained open to examination for federal
income tax purposes by the major tax jurisdictions to which the Company is subject. No tax returns are currently under examination
by any tax authorities.

11.       STOCK
OPTIONS AND WARRANTS

Stock
options

The
following is a summary of option activity during the years ended December 31, 2019 and 2020.

As
of December 31, 2020, all stock options outstanding are exercisable.

Stock
warrants

The
following is a summary of warrants activity during the years ended December 31, 2019 and 2020.

As
of December 31, 2020 , all stock warrants outstanding are exercisable.

12.       STOCKHOLDERS’
DEFICIT

The
Company is authorized to issue 200,000,000 shares of $0.001 par value common stock. The Company had 4,539,843 and 4,471,746 issued
and outstanding shares of common stock as of December 31, 2020 and December 31, 2019, respectively.

During
the year ended December 31, 2020, the Company issued 68,097 shares valued at $59,602 to investors in settlement of outstanding
stock payable.

13.       SUBSEQUENT
EVENTS

On January 27, 2021 the Company and Quoin agreed to revise the milestone
payments due under the Exclusive License Agreement to the following:

(i)       Successful completion
of Phase 2 testing: $250,000

(ii)       Successful completion
of Phase 3 testing: $500,000

(iii)       Regulatory approval
in US: $14,500,000

(iv)       Regulatory approval
in EU: $7,250,000

In addition as part the amendment the Companies
also agreed to extend the agreement indefinitely. 

None.

Item 9A. Controls and Procedures

As required by Rule 13a-15
under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and
procedures as of the end of the period covered by this annual report, being December 31, 2020. This evaluation was carried out
under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures
are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or
submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified
in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include controls and procedures
designed to ensure that information required to be disclosed in our company’s reports filed under the Securities Exchange
Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to
allow timely decisions regarding required disclosure.

Based upon that evaluation,
including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures
were ineffective as of the end of the period covered by this annual report.

Management’s Annual
Report on Internal Control over Financing Reporting

Our management is responsible
for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities
Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of December
31, 2020 based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission. As a result of this assessment, management concluded that, as of December 31, 2020, our internal control
over financial reporting was not effective. Our management identified the following material weaknesses in our internal control
over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and
effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect
to the requirements and application of both US GAAP and SEC guidelines.

We plan to take steps to enhance
and improve the design of our internal control over financial reporting. During the period covered by this annual report on Form
10-K, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement
the following changes during our fiscal year ending December 31, 2021: (i) appoint additional qualified personnel to address inadequate
segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting
and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing
to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may
be adversely affected in a material manner.

This annual report does not
include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s
report was not subject to attestation by our registered public accounting firm pursuant to an exemption for non-accelerated filers
set forth in Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

None 

PART
III

The following information
sets forth the names, ages, and positions of our current directors and executive officers.

Set forth below is a brief
description of the background and business experience of each of our current executive officers and directors.

Mr. Terry H. Howlett,
has been our Chief Executive Officer and Director since March 5, 1998. Mr. Howlett has a diversified background in market initialization
and development, sales and venture capital financing for emerging growth companies. He has held senior management, marketing and
sales positions with various companies, including the Canadian Federation of Independent Business, Family Life Insurance, and Avacare
of Canada and founded Presley Laboratories, Inc., which marketed cosmetic and skin, care products on a direct sales basis. For
the ten years prior to becoming President of the Company, Mr. Howlett was the President and CEO of Voice-it Solutions, Inc., a
publicly traded company on the Vancouver Stock exchange that made voice response software for order entry systems.

Mr. David St. James is
an inventor and businessman based in Las Vegas, Nevada. He has invented and co-invented turbochargers and superchargers, some of
which are in use today on production vehicles and in Formula 1. He has also been involved in other various aspects of the automotive
industry, including product development, service, and repair. He has been an Officer and Director of Homeland Resources Ltd. since
July of 2014 and currently serves as the President and a Director. He has been the Vice President and a Director of Nouveau Ventures
Inc. since August of 2014. Mr. St. James served as the President of XLR Medical Corporation from January 2009 through January 2012. 

Directors

Our bylaws authorize no less
than one (1) and more than twelve (12) directors. We currently have two directors.

Term of Office

Our Directors are appointed
for a one-year term to hold office until the next annual general meeting of our shareholders or until removed from office in accordance
with our bylaws. Our officers are appointed by our board of directors and hold office until removed by the board.

Significant Employees

Ms. Doreen McMorran,
is head of Business Development. Ms. McMorran brings to the Company almost 20 years of experience in the medical and pharmaceutical
industry, specifically in the areas of strategic planning, sales and marketing. She has spent the last seven years selling to international
dermatology and skincare focused companies like Procter and Gamble, Johnson & Johnson, Stiefel, Galderma, Novartis and Graceway,
to name a few. Ms. McMorran, who holds a Bachelor of Commerce (Honors) degree, spent six years in the pharmaceutical industry with
Astra Pharma. Additionally, she has held senior management level positions with a number of healthcare companies, focusing on business
development, sales, marketing and operations.

Family Relationships

There are no family relationships
between or among the directors, executive officers or persons nominated or chosen by us to become directors or executive officers.

Involvement in Certain
Legal Proceedings

To the best of our knowledge,
during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee:
(1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either
at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject
to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment
or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily
enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities;
and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission
to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Audit Committee

We do not have a separately
designated standing audit committee. The entire board of directors performs the functions of an audit committee, but no written
charter governs the actions of the board of directors when performing the functions of that would generally be performed by an
audit committee. The board of directors approves the selection of our independent accountants and meets and interacts with the
independent accountants to discuss issues related to financial reporting. In addition, the board of directors reviews the scope
and results of the audit with the independent accountants, reviews with management and the independent accountants our annual operating
results, considers the adequacy of our internal accounting procedures and considers other auditing and accounting matters including
fees to be paid to the independent auditor and the performance of the independent auditor.

We do not have an audit committee
financial expert because of the size of our company and our board of directors at this time. We believe that we do not require
an audit committee financial expert at this time because we retain outside consultants who possess these attributes as needed.

For the fiscal year ending
December 31, 2020, the board of directors:

1. Reviewed and discussed the
   audited financial statements with management, and
2. Reviewed and discussed the
   written disclosures and the letter from our independent auditors on the matters relating to the auditor’s independence.

Section
16(a) Beneficial Ownership Reporting Compliance

Section
16(a) of the Exchange Act requires our directors and executive officers and persons who beneficially own more than ten percent
of a registered class of the Company’s equity securities to file with the SEC initial reports of ownership and reports of
changes in ownership of common stock and other equity securities of the Company. Officers, directors and greater than ten percent
beneficial shareholders are required by SEC regulations to furnish us with copies of all Section 16(a) forms they file. To the
best of our knowledge based solely on a review of Forms 3, 4, and 5 (and any amendments thereof) received by us during or with
respect to the year ended December 31, 2020, the following persons have failed to file, on a timely basis, the identified reports
required by Section 16(a) of the Exchange Act during fiscal year ended December 31, 2020:

Code of Ethics

We adopted a Code of Ethics
for Financial Executives, which include our principal executive officer, principal financial officer, principal accounting officer
or controller, or persons performing similar functions. The Code of Ethics was filed as an exhibit to the annual report on Form
10KSB for the fiscal year ended December 31, 2004 and filed with the SEC on April 14, 2005.

Item
11. Executive Compensation

Compensation Discussion
and Analysis

Currently, the objective of
the cash compensation paid by the company is to provide fair reimbursement for the time spent by our executive officer and independent
directors to the extent feasible within the financial constraints faced by our developing business. The stock options granted to
our executive officer and to our independent directors are intended to provide these individuals with incentives to pursue the
growth and development of the company’s operations and business opportunities. Although the options awarded to our executive
and directors are typically exercisable immediately, they also remain valid and exercisable for terms of several years. We believe
this provides the proper balance of short-term and long-term incentives to increase the value of the company. Although an immediate
increase in share price following the issuance of the options would obviously result in a profit if those options were exercised,
the longer exercisable period of the options also provides an incentive to increase value over the long term and gives our executive
officer and directors the opportunity to realize gains based on the sustained growth of our operations and revenues.

In addition, our sole executive
officer holds substantial ownership in the company and is generally motivated by a strong entrepreneurial interest in expanding
our operations and revenue base to the best of his ability.

Summary Compensation Table

The table below summarizes
all compensation awarded to, earned by, or paid to our former or current executive officers for the fiscal years ended December
31, 2020 and 2019.

(1) Due to financial constraints,
however, the total paid to Mr. Howlett during the fiscal year ended December 31, 2020 was $0.

(2) Due to financial constraints,
however, the total salary paid to Mr. Howlett during the fiscal year ended December 31, 2019 was $0.

Narrative Disclosure
to the Summary Compensation Table

We granted Mr. Howlett
the right to convert his accrued compensation of $270,000 and $90,000 as of December 31, 2020 and 2019 into our common stock at
$1.00 per share at any time until 2022. If exercised, we also agreed to issue a three-year warrant to Mr. Howlett to purchase
an aggregate amount of 135,000 and 45,000 shares of common shares at a strike price of $1.50 per share for the years ended December
31, 2020 and 2019, respectively.

Outstanding Equity
Awards at Fiscal Year-End

The table below summarizes
all unexercised options, stock that has not vested, and equity incentive plan awards for each named executive officer as of December
31, 2020.

The table
below summarizes all compensation of our directors as of December 31, 2020.

Narrative Disclosure to
the Director Compensation Table

All the fees earned or paid
in cash and stock options awards granted to Terry Howlett were earned in connection with his service as an executive officer. Mr.
Howlett received no compensation for his service as a member of our board of directors.

Mr St. James was paid $6,000
for his services during the year ended December 31, 2020.

On September 22, 2018, we
granted an option to purchase 2,000 shares of our common stock to Mr. St. James. The options have a strike price of $1.75. The
stock options were exercisable upon grant and have a life of 5 years. The stock options were valued at $35,497 using the Black-Scholes
option pricing model.

The following table sets forth,
as of April 6, 2021, the beneficial ownership of our common stock by each executive officer and director, by each person known
by us to beneficially own more than 5{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of our common stock and by the executive officers and directors as a group.

Aside from that which follows
and in “Executive Compensation,” none of our directors or executive officers, nor any proposed nominee for election
as a director, nor any person who beneficially owns, directly or indirectly, shares carrying more than 5{14cc2b5881a050199a960a1a3483042b446231310e72f0dc471a7a1eddd6b0c3} of the voting rights
attached to all of our outstanding shares, nor any members of the immediate family (including spouse, parents, children, siblings,
and in-laws) of any of the foregoing persons has any material interest, direct or indirect, in any transaction for the last two
fiscal years or in any presently proposed transaction which, in either case, has or will materially affect us.

During the year ended December 31, 2019, the
Company sold furniture, fixtures and lab equipment to Ovation Science, a related party, for $75,000, the assets had been fully
depreciated by the Company in prior years and the Company recorded a gain from related party of $75,000 as a result of the sale.
Terry Howlett and Doreen McMorran control Ovation Science.

On February 3, 2020, we entered into a License
Agreement with Ovation Science, pursuant to which the Company granted to Ovation Science Inc. a license for the manufacture and
distribution rights to its hand sanitizer product, DermSafe. In exchange for the license, Ovation Science Inc. agreed to pay to
Skinvisible a percentage on all net sales on the licensed products subject to adjustment in certain situations plus a license fee
payable in year 3 of the agreement if it chooses to continue the license.

On June 10, 2020, Ovation Science Inc. paid
the Company the fee otherwise due in year 3 and in exchange the Company extended the term of Ovation’s license to 6-years
and granted Ovation additional rights to its hand sanitizer products and assigned Canadian Identification Numbers 02310589 and
02355558, all DermSafe Trademarks, DermSafe clinical data and the right to patent DermSafe where not currently patented. In exchange
for these rights Ovation paid a $100,000 license fee. The Company completed the required assignments during the year ending December
31, 2020 and recognized $100,000 in revenue.

The Company earned $15,861 in royalties under
the license agreement during the year ending December 31, 2020.

The Company sold polymer products to Ovation
Science Inc and earned $7,132 and 0 as of December 31, 2020 and 2019, respectively.

During
the year ended December 31, 2020, $27,000 was advanced by Terry Howlett and
$400 was repaid to Terry Howlett and $21,000 was repaid to Doreen McMorran.

As of December 31, 2020, $52,499
and $0 in advances remained due to Mr. Howlett and Ms. McMorran, respectively, and all other related party notes have been extinguished
or re-negotiated as convertible notes.

The following table
details the notes that are outstanding for Terry Howlett and Doreen McMorran.

Below is the table of Audit
Fees (amounts in US$) billed by our auditor in connection with the audit of the Company’s annual financial statements for
the years ended:

PART
IV

The following
financial statements and schedules listed below are included in this Form 10-K.

Financial
Statements (See Item 8)

SIGNATURES

Pursuant
to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.

Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.

I, Terry Howlett, certify that;

Date: April 15, 2021

/s/ Terry Howlett

By: Terry Howlett

Title: Chief Executive Officer

I, Terry Howlet, certify that;

Date: April 15, 2021

/s/ Terry Howlet

By: Terry Howlet

Title: Chief Financial Officer

CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND

CHIEF FINANCIAL OFFICER

PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002

In connection with the Annual Report of Skinvisible,
Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission
(the “Report”), I, Terry Howlett, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350,
as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

This certification has been furnished solely pursuant to Section
906 of the Sarbanes-Oxley Act of 2002.